198 related articles for article (PubMed ID: 28555080)
1. Deregulation of kinase signaling and lymphoid development in EBF1-PDGFRB ALL leukemogenesis.
Welsh SJ; Churchman ML; Togni M; Mullighan CG; Hagman J
Leukemia; 2018 Jan; 32(1):38-48. PubMed ID: 28555080
[TBL] [Abstract][Full Text] [Related]
2. EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications.
Schwab C; Ryan SL; Chilton L; Elliott A; Murray J; Richardson S; Wragg C; Moppett J; Cummins M; Tunstall O; Parker CA; Saha V; Goulden N; Vora A; Moorman AV; Harrison CJ
Blood; 2016 May; 127(18):2214-8. PubMed ID: 26872634
[TBL] [Abstract][Full Text] [Related]
3. The novel TERF2::PDGFRB fusion gene enhances tumorigenesis via PDGFRB/STAT5 signalling pathways and sensitivity to TKI in ph-like ALL.
Xu GF; Zeng Z; Zhang ZB; Zhang XM; Wang M; Xiao Q; Li J; Xie XQ; He S; Fu HH; Liu Y; Yang ZL; Chen Y; Shi J; Wang B; Qiu HY; Zhou Q; Liu Y; Chen SN
J Cell Mol Med; 2024 Feb; 28(3):e18114. PubMed ID: 38323741
[TBL] [Abstract][Full Text] [Related]
4. Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion.
Lengline E; Beldjord K; Dombret H; Soulier J; Boissel N; Clappier E
Haematologica; 2013 Nov; 98(11):e146-8. PubMed ID: 24186319
[No Abstract] [Full Text] [Related]
5. Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia.
Heltemes-Harris LM; Willette MJ; Ramsey LB; Qiu YH; Neeley ES; Zhang N; Thomas DA; Koeuth T; Baechler EC; Kornblau SM; Farrar MA
J Exp Med; 2011 Jun; 208(6):1135-49. PubMed ID: 21606506
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of imatinib and chemotherapy in a pediatric patient with Philadelphia-like acute lymphoblastic leukemia with
Fazio F; Barberi W; Cazzaniga G; Fazio G; Messina M; Della Starza I; De Propris MS; Mancini F; Mohamed S; Del Giudice I; Chiaretti S; Moleti ML; Guarini A; Foà R; Testi AM
Leuk Lymphoma; 2020 Feb; 61(2):469-472. PubMed ID: 31558067
[No Abstract] [Full Text] [Related]
7. Acute Lymphoblastic Leukemia Patient with Variant ATF7IP/PDGFRB Fusion and Favorable Response to Tyrosine Kinase Inhibitor Treatment: A Case Report.
Zhang G; Zhang Y; Wu J; Chen Y; Ma Z
Am J Case Rep; 2017 Nov; 18():1204-1208. PubMed ID: 29133777
[TBL] [Abstract][Full Text] [Related]
8. Multiple oligomerization domains of KANK1-PDGFRβ are required for JAK2-independent hematopoietic cell proliferation and signaling via STAT5 and ERK.
Medves S; Noël LA; Montano-Almendras CP; Albu RI; Schoemans H; Constantinescu SN; Demoulin JB
Haematologica; 2011 Oct; 96(10):1406-14. PubMed ID: 21685469
[TBL] [Abstract][Full Text] [Related]
9. [Acute lymphoblastic leukemia with EBF1-PDGFRB fusion gene: two cases report and literature review].
Chen YQ; Zheng YZ; Li J; Hua XL; Le SH
Zhonghua Xue Ye Xue Za Zhi; 2023 Jan; 44(1):69-71. PubMed ID: 36987727
[No Abstract] [Full Text] [Related]
10. Effective treatment with imatinib for acute B-lymphoblastic leukaemia with EBF1-PDGFRB fusion.
Horiuchi M; Yoshida M; Yamasaki K; Sakagami R; Aoyama T; Tatsumi N; Tsutsumi M; Nakaya Y; Fuseya H; Yoshimura T; Hayashi Y; Nakao T; Yamane T
Ann Hematol; 2021 May; 100(5):1329-1331. PubMed ID: 33150465
[No Abstract] [Full Text] [Related]
11. Interleukin-7 signaling in human B cell precursor acute lymphoblastic leukemia cells and murine BAF3 cells involves activation of STAT1 and STAT5 mediated via the interleukin-7 receptor alpha chain.
van der Plas DC; Smiers F; Pouwels K; Hoefsloot LH; Löwenberg B; Touw IP
Leukemia; 1996 Aug; 10(8):1317-25. PubMed ID: 8709637
[TBL] [Abstract][Full Text] [Related]
12. Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival.
Katerndahl CDS; Heltemes-Harris LM; Willette MJL; Henzler CM; Frietze S; Yang R; Schjerven H; Silverstein KAT; Ramsey LB; Hubbard G; Wells AD; Kuiper RP; Scheijen B; van Leeuwen FN; Müschen M; Kornblau SM; Farrar MA
Nat Immunol; 2017 Jun; 18(6):694-704. PubMed ID: 28369050
[TBL] [Abstract][Full Text] [Related]
13. ATF7IP as a novel PDGFRB fusion partner in acute lymphoblastic leukaemia in children.
Kobayashi K; Mitsui K; Ichikawa H; Nakabayashi K; Matsuoka M; Kojima Y; Takahashi H; Iijima K; Ootsubo K; Oboki K; Okita H; Yasuda K; Sakamoto H; Hata K; Yoshida T; Matsumoto K; Kiyokawa N; Ohara A
Br J Haematol; 2014 Jun; 165(6):836-41. PubMed ID: 24628626
[TBL] [Abstract][Full Text] [Related]
14. Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells.
Ishibashi T; Yaguchi A; Terada K; Ueno-Yokohata H; Tomita O; Iijima K; Kobayashi K; Okita H; Fujimura J; Ohki K; Shimizu T; Kiyokawa N
Exp Hematol; 2016 Mar; 44(3):177-88.e5. PubMed ID: 26703895
[TBL] [Abstract][Full Text] [Related]
15. Targeting hyperactive platelet-derived growth factor receptor-β signaling in T-cell acute lymphoblastic leukemia and lymphoma.
De Coninck S; De Smedt R; Lintermans B; Reunes L; Kosasih HJ; Reekmans A; Brown LM; Van Roy N; Palhais B; Roels J; Van der Linden M; Van Dorpe J; Ntziachristos P; Van Delft FW; Mansour MR; Pieters T; Lammens T; De Moerloose B; De Bock CE; Goossens S; Van Vlierberghe P
Haematologica; 2024 May; 109(5):1373-1384. PubMed ID: 37941480
[TBL] [Abstract][Full Text] [Related]
16. EBF1 and Pax5 safeguard leukemic transformation by limiting IL-7 signaling, Myc expression, and folate metabolism.
Ramamoorthy S; Kometani K; Herman JS; Bayer M; Boller S; Edwards-Hicks J; Ramachandran H; Li R; Klein-Geltink R; Pearce EL; Grün D; Grosschedl R
Genes Dev; 2020 Nov; 34(21-22):1503-1519. PubMed ID: 33004416
[No Abstract] [Full Text] [Related]
17. Early diagnosis of EBF1-PDGFRB-positive acute lymphoblastic leukemia.
Ishihara T; Watakabe M; Ochi S; Akisada N; Nogami K
Pediatr Int; 2022 Jan; 64(1):e14955. PubMed ID: 35289450
[No Abstract] [Full Text] [Related]
18. B-Cell Precursor-Acute Lymphoblastic Leukemia With EBF1-PDGFRB Fusion Treated With Hematopoietic Stem Cell Transplantation and Imatinib: A Case Report and Literature Review.
Sakurai Y; Sarashina T; Toriumi N; Hatakeyama N; Kanayama T; Imamura T; Osumi T; Ohki K; Kiyokawa N; Azuma H
J Pediatr Hematol Oncol; 2021 Jan; 43(1):e105-e108. PubMed ID: 32068648
[TBL] [Abstract][Full Text] [Related]
19. Ebf1 and c-Myb repress rag transcription downstream of Stat5 during early B cell development.
Timblin GA; Schlissel MS
J Immunol; 2013 Nov; 191(9):4676-87. PubMed ID: 24068669
[TBL] [Abstract][Full Text] [Related]
20. Inactivated STAT5 pathway underlies a novel inhibitory role of EBF1 in chronic lymphocytic leukemia.
Wang C; Li L; Li M; Shen X; Liu Y; Wang S
Exp Cell Res; 2021 Jan; 398(1):112371. PubMed ID: 33188849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]